Inncelerex provides expertise in:Modeling and SimulationClinical PharmacologyPharmacologyPre-clinical developmentIND enabling activitiesThe range of expertise listed above would enable pharmaceutical companies to have an integrated approach in search for signals of drug efficacy and safety at the early stages of development. This would in turn enable early Go/No Go decisions that lead to the selection of more promising projects and drug candidates and also lead to the discontinuation of less viable drug candidates, both of which would translate to an increase in cost-efficiency. Through affiliate companies, Inncelerex is also involved in IP development, IP acquisition, and R&D of:Innovative drug delivery platformsDrug candidates for metabolic diseasesDrug candidates for CNS indications
| Website | http://www.inncelerex.com |
| Revenue | $3 million |
| Employees | View employees |
| Address | 1 Evertrust Plz, Ste 1104, Jersey City, New Jersey 07302, US |
| Phone | +1 201-630-0350 |
| Industry | Drug Manufacturing & Research, Pharmaceuticals, Healthcare |
| Competitors | Thermo Fisher Scientific, ICON plc, PPD, Syneos Health, Parexel, Charles River Laboratories, Medpace, Covance, Celerion, Quintiles Transnational Holdings +33 more (view full list) |
| SIC | SIC Code 283 Companies, SIC Code 28 Companies |
| NAICS | NAICS Code 32541 Companies, NAICS Code 32 Companies, NAICS Code 3254 Companies, NAICS Code 325 Companies |
Looking for a particular Inncelerex employee's phone or email?
Inncelerex Questions
The Inncelerex annual revenue was $3 million in 2026.
Inncelerex is based in Jersey City, New Jersey.
The NAICS codes for Inncelerex are [32541, 32, 3254, 325].
The SIC codes for Inncelerex are [283, 28].
